This startup develops a data analytics platform that identifies existing non-cancer generic drugs with potential for cancer treatment. The platform synthesizes scientific and real-world data to discover and validate promising therapies for drug repurposing in oncology.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The traditional drug development process for cancer treatments is lengthy and expensive, often taking years and costing billions of dollars. Many existing, non-cancer generic drugs have shown anti-cancer evidence, but lack the funding and infrastructure for clinical trials needed to change the standard of care. Identifying and validating these promising therapies from the thousands of published research studies is a time-consuming process.
Solution
Reboot Rx is a health tech company that leverages AI and machine learning to accelerate the development of affordable cancer treatments by repurposing non-cancer generic drugs. Their technology synthesizes scientific and real-world data to identify the most promising drug candidates for repurposing in oncology, reducing the review time from years to weeks. Reboot Rx also addresses the funding gap for clinical trials of repurposed drugs by creating innovative and sustainable funding models. They collaborate with stakeholders to promote the adoption of new treatments in routine medical practice, ensuring that doctors and patients benefit from these affordable options.
Target Audience
The primary audience includes cancer patients, oncologists, researchers, and healthcare organizations seeking affordable and rapidly deployable cancer treatment options.
Features
- AI-powered platform that analyzes thousands of research studies to identify generic drugs with anti-cancer potential.
- Machine learning algorithms to validate promising therapies for drug repurposing in oncology.
- Innovative funding models to support clinical trials for repurposed generic drugs.
- Collaboration with healthcare stakeholders to influence the adoption of new treatments in routine medical practice.